A century ago, two oddly domestic puzzles helped set the rules for what modern science treats as "real": a Guinness brewer charged with quality control and a British lady insisting she can taste ...

Success is hard to come by in drug development. “On average, 50% of phase III trials with novel therapeutics fail,” says Subha Madhavan, vice president and head of AI/ML at Pfizer. “A primary reason ...

Every research lab is constantly innovating; either by creating something new or by understanding the equations and statistics underlying each vital subject, the stakes are high. With trillions of ...